

June 05, 2020

To,  
The Manager  
Listing Department,  
**The National Stock Exchange of India Limited**  
Exchange Plaza,  
Bandra Kurla Complex,  
Bandra (E), Mumbai – 400051

Dear Sir/Madam,

**Trading Symbol: ZOTA**

**Sub: Product Registration in Cambodia**

**Ref.: Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015**

Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015; we would like to inform you that we, Zota Health Care Limited (the "Company") have received product registration licenses for below mentioned 3 products from the Ministry of Health, Cambodia.

Sr. No.	Name of Product	Therapeutic Category
1	Zotamet-1000 (Tab – Each Tablet contains Metformin Hydrochloride 1000mg)	Antidiabetic
2	CDTEL-40 (Tab – Each Tablet contains Telmisartan 40mg)	Angiotensin II Antagonists
3	Amlozed-5 (Tab – Each Tablet contains Amlodipine 5mg)	Calcium Channel Blocker


We have received licenses of the aforementioned products for the validity period of five years; licenses of the products are also renewable. Company shall start exporting these products in the Cambodia very soon.

This is for your information and record.

Thanking you,

Yours faithfully,

For **Zota Health Care Limited**



**Ashvin Variya**  
**(Company Secretary & Compliance Officer)**  
Place: Surat



**Registered Office :**

Zota House, 2/896, Hira Modi Street,  
Sagrampura, Surat - 395 002 | Ph: +91 261 2331601  
Email: info@zotahealthcare.com  
Web : www.zotahealthcare.com  
CIN : L24231GJ2000PLCO38352

**Plant :**

Plot no. 169, Surat Special Economic Zone,  
Nr. Sachin Railway Station, Sachin,  
Surat - 394 230 (Guj.) India  
Ph: +91 261 2397122